MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
Reports, Plans, Studies, Proceedings, Analysis, Visualizations, Peer Reviewed Articles, Books, Publications, Rules & Policy Guidance
2022: BioPharmCatalyst_TOP 10 Cell and Gene Therapy Companies for 2022
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)
Organization & Developments: Rocket Pharma
Parents
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)
Children
*Focused on the development of gene therapies for the treatment of rare pediatric diseases.
*The company employs two modified non-pathogenic viruses to penetrate cells and deliver missing and properly functioning genetic material into targeted tissues
2018: Reader Inquiry: Is There Further Upside Ahead For Rocket Pharmaceuticals? - Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)
2019: How To Play This Rocket?
2022: Biotech Analysis Central Preview Series: Rocket Pharmaceutical_ seekingalpha.com
2022: Rocket Pharmaceuticals (RCKT) Investor Presentation - Slideshow_ seekingalpha.com
2022: Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher_ seekingalpha.com
2022: Rocket Pharmaceuticals: Intriguing Potential_ seekingalpha.com
2023: Rocket Pharma: Soars On Pivotal Danon Disease Study Agreement
2023: Rocket Pharmaceuticals: A Catalyst-Rich Year Ahead_ seekingalpha.com
2024: Rocket Pharmaceuticals: 2 Gene Therapy Candidates Anticipating Near-Term Review
2024: Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade)_ seekingalpha
2024: Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch
2024: Rocket Pharmaceuticals' Promising Path In Gene Therapy
2024: Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
2025: Rocket Pharma Is A Buy At These Prices With Promising Data_seekingalpha.com
2025: Rocket Pharmaceuticals cuts headcount, realigns pipeline
2025: Rocket Pharmaceuticals Stock (RCKT) Plummets 57% on FDA Intervention
2025: Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies
2025: Rocket Pharmaceuticals: Good News As Clinical Hold Lifted - But Challenges Remain
Jumps
*Key People: Rocket Pharma
Finance & Acquisitions: Rocket Pharma